Perspectives on complement and phagocytic cell responses to nanoparticles: From fundamentals to adverse reactions
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- Fulltext
Final published version, 7.49 MB, PDF document
The complement system, professional phagocytes and other cells such as Natural killer cells and mast cells are among the important components of the innate arm of the immune system. These constituents provide an orchestrated array of defences and responses against tissue injury and foreign particles, including nanopharmaceuticals. While interception of nanopharmaceuticals by the immune system is beneficial for immunomodulation and treatment of phagocytic cell disorders, it is imperative to understand the multifaceted mechanisms by which nanopharmaceuticals interacts with the immune system and evaluate the subsequent balance of beneficial versus adverse reactions. An example of the latter is adverse infusion reactions to regulatory-approved nanopharmaceuticals seen in human subjects. Here, we discuss collective opinions and findings from our laboratories in mapping nanoparticle-mediated complement and leucocyte/macrophage responses.
| Original language | English |
|---|---|
| Journal | Journal of Controlled Release |
| Volume | 356 |
| Pages (from-to) | 115-129 |
| ISSN | 0168-3659 |
| DOIs | |
| Publication status | Published - 2023 |
Bibliographical note
Funding Information:
S.M.M., A.C.H. and E.P. acknowledge support by the European Union's Horizon 2020 programme funded under H2020-EU.1.3. – Excellent Science – Marie Skłodowska-Curie Actions , grant agreement ID. 956544 (DIRNANO: Directing the Immune Response through Designed Nanomaterials). Z.S.F. (S. M. Discovery Group Ltd.) is a partner organisation in DIRNANO consortium. H.B.H. is an Early Stage Researcher financially supported by the DIRNANO programme . A.Y. & S.M.M. acknowledge support by the Danish Council for Independent Research – Technology and Production Sciences ; reference DFF-7017-00065. P.N.T. & S.M.M. acknowledge support by the European Union's Seventh Framework Programme (FP7-NMP-2012-Large-6) under the grant agreement no. 310337 (CosmoPHOS-nano Large-Scale Project). D.S. acknowledges support by the National Institute of Health grant R01AI154959 .
Funding Information:
Not only do the material properties play a modulatory role in nanoparticle interactions with the immune system, but also an inadvertent adsorption of non-specific biomolecules onto the surfaces of the nanoparticles could dynamically influence subsequent responses by the immune system. Future developments should carefully scrutinise and further study materials characteristics and map their immunological impact through systems immunology in relation to the developmental stages of diseases in validated animal models and humanised explant models that address intrinsic characteristics of different tissues. Indeed, some of the abovementioned suggestions are being investigated in the ongoing DIRNANO project, which is supported by the European Union's Horizon 2020 programme under Marie Skłodowska-Curie Actions. Our work in progress further considers and computes inter-individual immune responses to nanomedicines and correlates these to innate immunity genes and their polymorphisms. These approaches could pave the way for patient stratification in nanomedicine-based therapies.S.M.M. A.C.H. and E.P. acknowledge support by the European Union's Horizon 2020 programme funded under H2020-EU.1.3. – Excellent Science – Marie Skłodowska-Curie Actions, grant agreement ID. 956544 (DIRNANO: Directing the Immune Response through Designed Nanomaterials). Z.S.F. (S. M. Discovery Group Ltd.) is a partner organisation in DIRNANO consortium. H.B.H. is an Early Stage Researcher financially supported by the DIRNANO programme. A.Y. & S.M.M. acknowledge support by the Danish Council for Independent Research – Technology and Production Sciences; reference DFF-7017-00065. P.N.T. & S.M.M. acknowledge support by the European Union's Seventh Framework Programme (FP7-NMP-2012-Large-6) under the grant agreement no. 310337 (CosmoPHOS-nano Large-Scale Project). D.S. acknowledges support by the National Institute of Health grant R01AI154959.
Funding Information:
Not only do the material properties play a modulatory role in nanoparticle interactions with the immune system, but also an inadvertent adsorption of non-specific biomolecules onto the surfaces of the nanoparticles could dynamically influence subsequent responses by the immune system. Future developments should carefully scrutinise and further study materials characteristics and map their immunological impact through systems immunology in relation to the developmental stages of diseases in validated animal models and humanised explant models that address intrinsic characteristics of different tissues. Indeed, some of the abovementioned suggestions are being investigated in the ongoing DIRNANO project, which is supported by the European Union's Horizon 2020 programme under Marie Skłodowska-Curie Actions. Our work in progress further considers and computes inter-individual immune responses to nanomedicines and correlates these to innate immunity genes and their polymorphisms. These approaches could pave the way for patient stratification in nanomedicine-based therapies.
Publisher Copyright:
© 2023 The Authors
- Adverse reactions, Complement system, Dendrimers, Macrophage, NanoLigand carriers, Nanoparticles, Opsonisation, Pseudoviral nanoparticles, phagocytosis
Research areas
ID: 339333336